About AviadoBio
AviadoBio is a Healthcare company based in London (United Kingdom) founded in 2019 by Do Young Lee and Youn Bok Lee. Developer of gene therapies for neurodegenerative disorders. AviadoBio has raised $80 million across 1 funding round from investors including Life Sciences Partners, LifeArc and NEA. The company has 38 employees. Its chief executive, as recorded, is Lisa Deschamps. AviadoBio offers products and services including AVB-101 and Gene Therapy Pipeline. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is AVIADOBIO LTD.
Company details
AviadoBio was founded in 2019 in London, United Kingdom, as a biotechnology firm focused on gene therapies for neurodegenerative conditions. Therapies are developed for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The lead candidate, AVB-PGRN, is an adeno-associated virus-based therapy designed for patients with FTD caused by progranulin (GRN) gene mutations. Operations center on advancing clinical-stage gene delivery solutions.
- Headquarters London, United Kingdom
- Employees 38
- Founders Do Young Lee, Youn Bok Lee
- SectorsHealthcare
- Website aviadobio.com
- Social LinkedIn X
- Legal Name Aviadobio Ltd
- Date of Incorporation 20 Dec, 2019
- Jurisdiction LONDON, ENGLAND
- Net Profit-$9.12 M (USD)-766as on Dec 31, 2021
- EBITDA-$11.8 M (USD)-723as on Dec 31, 2021
- Total Equity Funding$80M (USD)
in 1 rounds
- Latest Funding Round$80M (USD), Series A
Dec 2021
- InvestorsLife Sciences Partners
& 7 more
- Employee Count38
Products & Services of AviadoBio
AviadoBio offers a comprehensive portfolio of products and services, including AVB-101 and Gene Therapy Pipeline.
Targets genetic sub-type of frontotemporal dementia through clinical trials
Develops treatments for ALS and other neurodegenerative conditions
Funding Insights of AviadoBio
AviadoBio has successfully raised a total of $80M through 1 strategic funding round. The most recent funding activity was a Series A round of $80 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80M
- Total Rounds 1
- Last Round Series A — $80M
- First Round $80M
(Dec 2021)
- Investors Count 8
All 1 funding rounds of AviadoBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $80M | Series A | – | New Enterprise Associates, Monograph |
8 investors in total: 8 institutional.
Investors in AviadoBio
AviadoBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Life Sciences Partners, LifeArc and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Monograph Capital is focused on life sciences investment. | monograph.bio | |||
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Venture capital fund investing in early-stage healthcare startups | ddf.vc | Boston, United States | ||
Medical research and treatments are supported by the community foundation. | 1992 | lifearc.org | London, United Kingdom | |
| jnjinnovation.com |
Investor details for AviadoBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AviadoBio
44 people are tracked at AviadoBio (22 in leadership, 11 in board & advisors, 11 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Do Young Lee | Co-Founder | Leadership |
Youn Bok Lee | Co-Founder | Leadership |
Lisa Deschamps | CEO | Leadership |
John Lavarino | Senior Director People | Leadership |
Leanne Dronfield | DIRECTOR, CLINICAL OPERATIONS | Leadership |
Vipul Bhakta | Director, Facilities Operations | Leadership |
Ana Perez | VP Of Finance | Leadership |
Chris Powell | Vice President Clinical Operations | Leadership |
Rachel Sartaj | Associate Clinical Development And Medical Affairs Director | Leadership |
David Cooper | Chief Medical Officer | Leadership |
Andrettie Martinsson | Associate Director, Finance | Leadership |
Daniel Ring | Vice President, Business Development & Licensing | Leadership |
Louise Rowe | VP Program & Alliance Management | Leadership |
Farah Speer | Senior Vice President, Corporate Communications & External Relations | Leadership |
Alex Bloom | Chief Technology Officer | Leadership |
Graeme Fielder | Chief Operating Officer | Leadership |
Christopher E Shaw | Chief Scientific And Clinical Advisor | Leadership |
Gurdeep Kooner | Director | Leadership |
Catia Andreassi | Director | Leadership |
Anna Ettorre | Director Translational Science, Bioassays and Biomarkers | Leadership |
24 more people are available in the full profile.
Complete people profiles for AviadoBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AviadoBio
2 dated milestones of AviadoBio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded AviadoBio is founded.
- Funding First funding round of $80.0M.
Web traffic of AviadoBio
The website of AviadoBio (aviadobio.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 130% vs previous month
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as AviadoBio (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aviadobio
Complete news archive for AviadoBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AviadoBio
AviadoBio was founded in 2019 and raised its 1st funding round 2 years after it was founded.
AviadoBio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Lisa Deschamps is the CEO of AviadoBio, as recorded in our data.
AviadoBio is a funded company, having raised a total of $80M across 1 funding round to date. The company's 1st funding round was a Series A of $80M, raised on Dec 2021.
AviadoBio has 38 employees.
AviadoBio was founded in 2019 in London, United Kingdom, as a biotechnology firm focused on gene therapies for neurodegenerative conditions. Therapies are developed for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The lead candidate, AVB-PGRN, is an adeno-associated virus-based therapy designed for patients with FTD caused by progranulin (GRN) gene mutations. Operations center on advancing clinical-stage gene delivery solutions.
AviadoBio offers AVB-101 and Gene Therapy Pipeline.
AviadoBio has 8 investors. Key investors include Life Sciences Partners, LifeArc, NEA, Monograph Capital, and Advent Life Sciences.
AviadoBio operates through Aviadobio Ltd.